Litigation Details for Exelixis, Inc. v. MSN Laboratories Private Limited (D. Del. 2019)
✉ Email this page to a colleague
Exelixis, Inc. v. MSN Laboratories Private Limited (D. Del. 2019)
| Docket | ⤷ Try a Trial | Date Filed | 2019-10-29 |
| Court | District Court, D. Delaware | Date Terminated | 2023-01-29 |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | Sherry R. Fallon |
| Parties | MSN LABORATORIES PRIVATE LIMITED | ||
| Patents | 10,034,873; 10,039,757; 7,579,473; 8,497,284; 8,877,776; 9,000,002; 9,000,021; 9,000,038; 9,024,007; 9,724,342 | ||
| Attorneys | Richard Juang | ||
| Firms | Heyman Enerio Gattuso & Hirzel LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Exelixis, Inc. v. MSN Laboratories Private Limited
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Biologic Drugs cited in Exelixis, Inc. v. MSN Laboratories Private Limited
The biologic drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for Exelixis, Inc. v. MSN Laboratories Private Limited (D. Del. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2019-10-29 | 1 | Complaint | BACKGROUND 18. U.S. Patent No. 8,877,776 (“the ’776 Patent”), entitled “(L)-malate salt of…Product”) prior to the expiration of U.S. Patent No. 8,877,776. … INFRINGEMENT OF US PATENT NO. 8,877,776 28. Exelixis incorporates each…FOR PATENT INFRINGEMENT 1. This is an action for patent infringement under the patent laws…November 4, 2014. The ’776 Patent will expire on October 8, 2030. The ’776 Patent claims crystalline Form | External link to document |
| 2021-07-15 | 164 | Redacted Document | 09 00 21 14 - # %$ …2019 30 January 2023 1:19-cv-02017 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2021-09-08 | 196 | Notice of Service | Initial Invalidity Contentions for U.S. Patent Nos. 7,579,473 and 8,497,284 [CONFIDENTIAL] filed by MSN…2019 30 January 2023 1:19-cv-02017 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2021-09-08 | 197 | Notice of Service | Initial Invalidity Contentions for U.S. Patent No. 8,877,776 (with Exhibit A) [HIGHLY CONFIDENTIAL]; …2019 30 January 2023 1:19-cv-02017 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2021-09-08 | 198 | Notice of Service | Infringement Contentions Concerning U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284, and (3) Exelixis …Supplemental Infringement Contentions Concerning U.S. Patent No. 8,877,776 filed by Exelixis, Inc..(Raucci, …2019 30 January 2023 1:19-cv-02017 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2021-10-12 | 205 | Notice of Service | Munson, Ph.D. Concerning Infringement of U.S. Patent No. 8,877,776 filed by Exelixis, Inc..(Raucci, Anthony…2019 30 January 2023 1:19-cv-02017 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2021-10-13 | 206 | Notice of Service | Invalidity of the Asserted Claims of U.S. Patent Nos. 7,579,473 and 8,497,284 (with Exhibits A-B); (ii) …Salvatore Lepore Regarding Invalidity of U.S. Patent Nos. 7,579,473 and 8,497,284 (with Exhibits A-B); and, …Regarding Invalidity of the Asserted Claims of U.S. Patent Nos. 8,877,776 (with Exhibits A-B) filed by MSN…2019 30 January 2023 1:19-cv-02017 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
